Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Parma – page 2

219 clinical trials in Parma, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Parma at a glance
219
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

219 trials in Parma

Open in trial search

Kidney transplant rejection

Recruiting

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Rinatabart Sesutecan with Pegfilgrastim in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Ovarian epithelial cancer

Recruiting

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Mantle cell lymphoma

Recruiting

A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fondazione Italiana Linfomi Ets

Hepatitis D

Recruiting

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BJT-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Transitional cell carcinoma metastatic

Recruiting

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:AstraZeneca AB

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Parma

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, lung cancer, and breast cancer treatments. Investigations include innovative immunotherapy approaches and targeted therapies for various cancer types.

  • Novel therapies for NSCLC patients
  • Triple-negative breast cancer treatments
  • Multiple myeloma management strategies

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Respiratory Medicine

Studies examining treatments for respiratory syncytial virus (RSV) infections in high-risk populations. Advanced research into preventive therapies and management strategies.

  • RSV prevention in infants
  • Respiratory support strategies
  • Critical care ventilation protocols

Focus on developing protective measures for vulnerable patient populations.

03 Transplant Medicine

Clinical trials evaluating new approaches to kidney transplantation and prevention of complications. Research on reducing delayed graft function and improving transplant outcomes.

  • Post-transplant care optimization
  • Graft function improvement
  • Novel immunosuppressive strategies

Emphasis on enhancing long-term transplant success rates.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.